Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01616680

Study Title
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease (NCT01616680)

Trial Description
The purpose of this research is to test the safety and efficacy of brentuximab vedotin (also known as SGN-035) in patients with acute skin graft-versus-host disease or GVHD.

This trial is sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium/ National Cancer Institute (NCI) [1]

Study Data

  • Condition: Graft vs. Host Disease (GVHD)
  • Interventions:
  • Phase: II
  • Enrollment: 0
  • Start: September 2012
  • Estimated Primary Completion: June 2016 (Final data collection date for primary outcome measure)
  • Last verified: June 2013

Study Schematic

Screen Shot 2016-07-06 at 4.34.34 PM


Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar